SipNose


SipNose is a company specializing in innovative intranasal drug delivery technology aimed at improving efficacy, safety, and patient compliance. Their platform enables targeted delivery to the brain and other therapeutic applications, including treatments for neurological disorders and COVID-19. They collaborate with pharmaceutical companies and hold a device master file at the FDA, with a pipeline of drug-device combination products.

Industries

biopharma
biotechnology
health-care
medical-device
pharmaceutical

Nr. of Employees

small (1-50)

SipNose

13 Hayetzira St. Yokneam Israel 2066720


Patents

Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization

US-12329902-B2

View Details

Devices and methods for delivering a substance to a body cavity

US-11992604-B2

View Details

Adjustable dosing delivery and multi sectioned drug compartment

US-11471618-B2

View Details

Device to deliver a predetermined amount of a substance to a natural orifice of the body

US-11383048-B2

View Details

Device and method for aerosolized delivery of substance to a natural orifice of the body

US-11278682-B2

View Details

Device and method for aerosolized delivering of substance to a natural orifice of the body

US-11116914-B2

View Details
View All Patents

Products

Single-use intranasal delivery device

A disposable device intended for everyday or emergency intranasal administration suitable for home or clinical settings.

Multi-dose intranasal delivery device

A device architecture supporting multiple doses for repeated administration scenarios; tailored variants for different use cases.

Reusable device with disposable nosepiece

A reusable functional unit paired with a disposable nosepiece to combine durability with single-use patient contact components.

Intranasal nitric-oxide based antiviral therapy (platform product)

A portable intranasal therapy using gaseous nitric oxide delivery and/or NO-donor compounds for localized antiviral activity at the nasal mucosa, intended for early-stage post-exposure treatment or reduction of viral load.


Services

Tailoring the intranasal delivery platform to accommodate partner antiviral agents, vaccines, or other therapeutics with minimal reformulation.

Co-development collaboration to apply the intranasal platform for mucosal immunization, prophylaxis, or early-stage treatment of respiratory infections.

Preparation and maintenance of regulatory documentation including device master file submissions and strategy for 505(b)(2) drug-device combination approvals.

Expertise Areas

  • Nose-to-brain drug delivery
  • Intranasal vaccination and mucosal immunization
  • Intranasal antiviral therapy development
  • Drug-device combination product development (505(b)(2) pathway)
  • Show More (4)

Key Technologies

  • Intranasal aerosol delivery
  • Plume geometry optimization for upper nasal deposition
  • Compressed-air aerosol generation
  • Dry powder and liquid nasal formulation delivery
  • Show More (4)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.